CClinicalTrials.gg
RecruitingNCT07366827Updated Apr 24, 2026

Effectiveness of Motorised Lumbar Support for Non-specific Low Back Pain

An interventional study of Motorized lumbar support and Standard lumbar support in Non-specific Low Back Pain, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Laval University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Low back pain (LBP) represents a common musculoskeletal conditions worlwide, causing substantial disability and economic burden. While traditional semi-rigid lumbar supports are commonly prescribed to alleviate LBP symptoms, their effectiveness remains limited by their static mechanical properties and lack of adaptability to movement patterns. Motorized lumbar support offer a novel approach by allowing the application of controlled decompressive forces while maintaining functional mobility. This experimental study aims to compare the effectiveness between a motorized lumbar support and a standard semi-rigid support in adults with non-specific LBP. Seventy adults with non-specific low back pain (LBP) will be recruited. Primary outcomes (pain intensity and physical functioning [daily average]) will be collected daily, while secondary outcomes (average pain intensity over the last week, pain-related disability, etc.) will be assessed at baseline, 3 and 9 weeks after randomization.

Read the detailed description

LBP represents a common musculoskeletal conditions, causing substantial disability and economic burden. Several strategies, such as education, exercise, manual therapy, psychological techniques and lumbar supports have been recommended for LBP mangement. While traditional semi-rigid lumbar supports are commonly prescribed to alleviate LBP symptoms, their effectiveness remains limited by their static mechanical properties and lack of adaptability to movement patterns. A motorized lumbar support, may offer a novel approach through application of controlled decompressive forces while maintaining functional mobility. An innovative battery-powered orthosis that provides adjustable traction between thoracic and pelvic components, potentially addressing underlying mechanical factors contributing to pain, will be tested in participants with chronic LBP.

This single-blind, parallel-group clinical trial aims to compare the effectiveness of a motorized lumbar support with that of a standard semi-rigid lumbar support in adults suffering from non-specific LBP. Eligible participants will be adults aged 18 to 65 years experiencing LBP with an average pain score of at least 3 out of 10 in the past week, pain related-disability ≥10% at ODI, and pain relief must be present during manual traction (measured by a moderate improvement (+3) on a global rating of change scale. Exclusion criteria include specific spinal pathologies (e.g., fractures, spinal stenosis, cancer), presence of neuropathic pain (leg and back, of 4 at the DN4), pregnancy, high BMI (>32), respiratory and circulatory issues, osteoporosis, recent rib or pelvic fractures, and any contraindications to wearing lumbar supports. A total of 70 participants will be randomly assigned to wear either a motorized lumbar support or a semi-rigid lumbar support . The motorized lumbar support is a battery-powered lumbar orthosis with thoracic and abdominal belts connected by lateral supports. It applies adjustable decompression force to the spine while allowing movement. Each participant will be instructed to wear the assigned support for at least four hours per day over three weeks, excluding while sleeping.

To minimize bias in data collection, subjective variables will be evaluated using REDCap while objective variables will be collectedat research centre. The primary outcomes include daily pain intensity and physical functioning. Secondary subjective outcomes include pain-related disability, average pain intensity of the past week, pain catastrophizing, fear of movement, self-efficacy, acceptability and adverse effects.

The statistician performing the statistical analyses will be blinded to group allocation. Linear mixed models incorporating fixed effects for group (motorized vs. standard support), time, and their interaction, with participants included as a random effect will be used. Daily wearing of the lumbar support, age and self-reported sex will be included as covariates. Intention-to-treat will be used for the main analyses. Per-protocol analyses will be conducted as sensitivity analyses, with the latter including only those who adhered to the recommended usage (minimum 4 hours/day, 5 days/week for 3 weeks). The sample size of 70 participants (35 per group) is planned based on the ability to detect a 2-point difference on the pain scale, with 95% power, a significance level of 0.05, and an estimated 20% dropout rate.

02

Conditions studied

  • Non-specific Low Back Pain

Keywords

  • non-specific low back pain
  • motorized lumbar support
  • standard lumbar support
03

In context

Lead sponsor

Laval University is the lead sponsor of 371 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults between 18 and 65 years old with non-specific low back pain.
  • Average pain level of ≥3 out of 10 during the previous week.
  • Pain-related disability ≥10% at ODI.
  • Pain relief must be present during manual traction, measured by a moderate improvement (+3) on a global rating of change scale (anchors: -7 to +7).

Exclusion criteria

Exclusion Criteria:

  • Specific cause of low back pain (e.g., fracture, cancer, spinal stenosis, severe spondylolisthesis)
  • Presence of neuropathic pain (leg or back of 4 at the DN4).
  • Pregnancy.
  • Body mass index > 32.
  • Waist size between 74 and 115 cm.
  • Respiratory and circulatory conditions.
  • Osteoporosis.
  • Paraplegia and hemiplegia.
  • Abdominal wounds at the site of the orthosis.
  • Rib or pelvic fractures less than 3 months.
  • Presence of electronic medical device.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Motorized lumbar support

    The motorized lumbar support is battery-powered orthosis providing adjustable traction between thoracic and pelvic components, and apply controlled decompressive forces while maintaining mobility.

    Other: Motorized lumbar support

  • Active comparator
    Standard lumbar support

    This is a semi-rigid lumbar support featuring six steel stays, elastic side panels, and a neoprene wrap that allows for individualized adjustment.

    Other: Standard lumbar support

Interventions

  • OtherMotorized lumbar support

    Participants will be advised to wear motorized lumbar support for a minimum of 4 hours and a maximum of 8 consecutive hours per day throughout the three-week study period. To reach the target of 4 hours, participants will gradually increase their daily wear time : 2 hours on the first day, 3 hours on the second day and 4 hours on the third day.

  • OtherStandard lumbar support

    Participants will be advised to wear motorized lumbar support for a minimum of 4 hours and a maximum of 8 consecutive hours per day throughout the three-week study period. To reach the target of 4 hours, participants will gradually increase their daily wear time : 2 hours on the first day, 3 hours on the second day and 4 hours on the third day.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    The numeric scale from 0 to 10 (0: no pain; 10: worst imaginable pain) will be used to rate average pain intensity experienced during the day.

    Time frame: Once a day for three weeks.

  2. Physical functioning

    The numeric scale from 0 to 10 (0: no difficulty functioning; 10: inability to function) will be used to rate the ability to carry out daily activities.

    Time frame: Once a day for three weeks.

Secondary outcomes

  1. Pain-related disability

    The Oswestry Disability Index (ODI) is a validated and reliable 10-item questionnaire (0 = no disability; 100 = extremely severe disability) recommended for evaluating physical functioning in individuals with LBP.

    Time frame: Baseline, week 3 and 9.

  2. Pain intensity

    The 11-point Numeric Rating Scale (0 = "no pain" to 10 = "the worst pain you can imagine") will be used to measure the average pain intensity over the past week.

    Time frame: Baseline, week 3 and 9.

  3. Pain catastrophizing

    Pain catastrophizing will be evaluated using the Pain Catastrophizing Scale. The Pain Catastrophizing Scale (PCS) is a self-administrated questionnaire of 13 questions measuring catastrophizing thoughts contributing to pain on a 5-point likert scale ranging from 0 ("not at all", low level of catastrophizing thoughts) to 5 ("all the time", high level of catastrophizing thoughts).

    Time frame: Baseline, week 3 and 9.

  4. Fear of movement

    The Tampa Scale of Kinesiophobia is a self-administrated questionnaire used to assess fear of movement using 17 questions on a 4-point scale ranging from 1 ("strongly disagree", low level of kinesiophobia) to 4 ("strongly agree", high level of kinesiophobia).

    Time frame: Baseline, week 3 and 9.

  5. Pain self-efficacy

    Pain self-efficacy will be evaluated using the Pain Self-Efficacy Questionnaire. The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-item questionnaire measuring the confidence people with ongoing pain have in performing activities while in pain, on a 10-point scale from 0 ("not at all confident", low self-efficacy) to 10 ("completely confident", high self-efficacy).

    Time frame: Baseline, week 3 and 9.

  6. Acceptability

    Acceptability of wearing the lumbar support will be evaluated using the Theoretical Framework of Acceptability.

    Time frame: Week 3

  7. Acceptance

    Acceptance will be measured using the extended version of the Unified Theory of Acceptance and Use of Technology (UTAUT2).

    Time frame: 3 weeks

  8. Adverse events

    All adverse will be documented and reported.

    Time frame: 3 weeks

Other outcomes

  1. Perceived effect of the lumbar support

    A "global rating of changes" question type ( "today, what was the effect of wearing the lumbar support") on a 15-point scale (-7 to +7, with -7 = "very great deal worse"; 0 = "no effect" ; +7 = "very great deal better") will be used. The perceived effect of the lumbar support will be used only in the per protocol sensitivity analysis.

    Time frame: Once a day for three weeks.

07

Study locations

1 of 1 sites recruiting
  • Centre interdisciplinaire de recherche en réadaptation et intégration sociale (CIRRIS)
    Québec, Quebec G1M 2S8, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD) underlying the results reported in the published article will be made available. The study protocol will also be published.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07366827
Lead sponsor
Laval University
Collaborators
Corset Saint-Francis, MedTeq
Responsible party
Hugo Massé-Alarie (Associate Professor, Laval University) — Principal investigator
First posted
Jan 26, 2026
Start date
Feb 16, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Hugo Massé-Alarie, PhD
Contact
hugo.masse-alarie@fmed.ulaval.ca
+1 (418) 529 9141
Hugo Massé-Alarie, PhD
principal investigator · Laval University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion